Actively Recruiting
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-11-24
416
Participants Needed
6
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia. Numerous studies show that the rapidity of the initial management of FPE would reduce the risk of negative evolution and would have a decisive impact on the short and long term prognosis. The rapidity of this management can be measured by the duration of untreated psychosis, or DUP (Duration of Untreated Psychosis), the time interval between the appearance of the first frank psychotic symptoms and the initiation of adequate psychiatric care. The objective of this study is to show the impact of an intervention facilitating access to specialized care for PEP on the reduction of DUP. This intervention consists of an early identification program for FPE, the PRESTO program, specifically targeting 3 determining steps in the reduction of DUP: * Informing the general population about psychotic disorders * Knowledge of front line actors (APL: general practitioners, school and university medicine, teenager's house, associative networks educators, emergency services, firefighters, etc.) about FPE and its management * Articulation between APL and specialized psychiatric care
CONDITIONS
Official Title
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder according to DSM-5
- No prior neuroleptic treatment for antipsychotic purposes except for current episode and less than 6 months
- Oral consent given by the patient or parents if the patient is a minor
You will not qualify if you...
- Patients already treated and followed for first-episode psychosis
- Brief psychotic state not requiring specific management
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Hospices Civils de Lyon
Bron, France, 69500
Actively Recruiting
2
Chu Clermont-Ferrand
Clermont-Ferrand, France, 63003
Actively Recruiting
3
Chu Grenoble
Grenoble, France, 38000
Actively Recruiting
4
CHU de Montpellier
Montpellier, France, 34090
Actively Recruiting
5
CHU de Nîmes
Nîmes, France, 30900
Actively Recruiting
6
Chu Saint Etienne
Saint-Etienne, France, 42100
Actively Recruiting
Research Team
E
Eric FAKRA, MD PhD
CONTACT
A
Amandine BAUDOT, CRA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here